We had another terrific networking event in Asbury Park last week. Good to see so many insiders connecting. I even witnessed some business conducted by two small-business women who came specifically to our event to wrap up a deal. Plenty of others mentioned how they made plans to meet with clients.
Here’s a photo gallery of the events (and link to the recap story.)
A big thanks to our presenting sponsor, Hance Construction. And our supporting sponsors, HBK CPAs & Valuations, Cova Software, McLaughlin & Stern law, UFCW, Treez, Zenco and U.S. Payment Services LLC.
Mollie Hartman Lustig said something I can’t resist noting here: “NJ Cannabis Insider events just keep getting better and better each time.” And I can’t take that kind of praise alone, so please remember, these awesome events are thanks to our events staff: Kristen Ligas, Niyala Shaw, Priscilla Pierre and Heather Long.
Just wish we didn’t have to turn folks away at the door. We were at the Asbury Hotel’s posted capacity fairly early. It’s a hint not to wait until the last minute for our next event…
Speaking of events, our next big one is Sept. 15 at the Crown Plaza Princeton, presented by Weedmaps. The networking sessions we’ve carved out as well as the program we have in store is going to knock your socks off. Read a little about it below.
Inside this issue:
- Analysis: Breaking down the CRC’s demographic stats from conditional licensees
- Q&A with Vlad Bautista, founder of Happy Munkey
- Prof. Mejia’s Corner: Digging up the facts on magic mushrooms
- Research: What psilocybin mushrooms can do for patients in N.J.
- D.C. Report: Bill to end prohibition, boost research, social equity introduced to U.S. Senate
- Bootcamp time! Sept. 15 event aimed to boost small businesses.
- Live virtual job fair July 26-27
You may have seen we’re revamping how we present information. Now that the market is open, we want to ensure we’re getting you the information and contacts you need. Let us know.
Finally, send us your events listings and press releases: Email us at [email protected], and follow us on Linkedin.
Take care, until next time…
— Enrique Lavin
Analysis: Breaking down the CRC’s recent demographic stats from conditional licensees
The Cannabis Regulatory Commission has started releasing demographic data, a lot of which deals with conditional licenses. We thought it was a good time to take an overview of that data, and talk about where it could go on both the state and municipal level alongside many of the factors that are going to be on the horizon as the market develops.
The conditional license category makes up the largest percentage of licensees that have been approved. That means that a lot of these numbers are subject to change when it comes to seeing who is and isn’t able to secure the real estate, zoning, construction and capital that’s necessary to actually make those businesses a reality. That survivability ratio is going to be critical.
Cultivators comprise the largest percentage of those conditional licenses, followed by manufacturers and retailers.
When it comes to the cultivators, an estimated 50% have been classified as diversely owned businesses and roughly 20 out of 45 for the manufacturers. For retail it was roughly 3 out of 11.
For ethnic and racial demographics, Black, white and Hispanic made up the largest identifiable shares. That being said, the number of those that fall in the “other or not listed” category is sizable and would make it the third highest behind the white category. If added to the “not disclosed” category that would actually make it the second highest.
An estimated 38% are majority owners with prior marijuana convictions.
On the horizon with the commission
The CRC has also alluded to putting even more data measures in place.
“Once we have our employee badging, our cannabis ID card system operational, it will not only then be collecting demographic data on race, ethnicity and gender on ownership principals, the managers, the license applicants — but also employees in this industry so that we can not only report out what the management teams of these companies look like, but also what the employee base is like,” said executive director Jeff Brown in a monthly May meeting.
Should those things happen it could be game changing since this would be one of the few, if only instances of a government agency gathering such data on an entire industry.
Data can also be gathered at the municipal level. When Jersey City officials were pressed by the NJ Cannabis Insider on whether they would start gathering demographic data from their applicants, they indicated they would.
From the previous meeting I was at, applicants were asked for demographic information that included race and also country of origin and religion if they so chose to identify.
Moves like these are important, because it gives local residents in each municipality a clear picture of what their market actually looks like when it comes to the cannabis businesses that are touching down in their community.
Whether or not other municipalities follow suit will be closely watched. Municipalities are technically in the best position to give even more detailed data on who the applicants are and how they are doing.
One example is the use of host and community agreements. A lot of applicants are talking about the plethora of work they are going to do for communities. How that work is tracked and what the data on that work looks like will fall in the municipalities wheelhouse. Understanding what the municipality has asked of each applicant and scrutinizing those asks will also be critical.
In the end, the conversation around data is just starting, but it is by no means at an end anytime soon. That data can shape what transparency and accountability for both companies and government officials look like down the road.
— Jelani Gibson
We catch up with Vlad Bautista of Happy Munkey, an events company with legacy market ties that recently threw a 7/10 event across the Hudson that drew its fair share of New Jerseyans. In this interview, we pulled up to the party to talk about the legacy-to-legal transition, the future of cannabis hospitality and more.
Q: What is the best selling point that you have about cannabis life as opposed to all of the other lifestyles that are being marketed?
A: Cannabis is a community-sharing thing. I think that people enjoy spaces where they are communicating and sharing experiences together with cannabis. Cannabis enhances every experience and I think that is what we’re going to see now. Things like being on a rooftop in Chelsea, that’s historical. Cannabis consumers are usually the coolest part of every sector and culture.
Q: What makes a good cannabis hospitality event?
A: Before we started doing events in the New York and tri-state area it was more of the farmers’ market sort of events.
A key component is making it very experiential and not so much about purchasing more — more about people experiencing things in different ways, really knowing how to curate the crowd and the music for everyone. Have cool setups and different installations for people to experience.
Q: What type of experience does Happy Munkey sell?
A: Happy Munkey sells the experience that you will be sitting with all sorts of people from all walks of life that you never would have met in any other setting and we are continuing to break the glass ceilings. Continuing to push cannabis and minorities, Black and brown people, to do this at the highest level is what Happy Munkey is moving.
Q: What does social equity in cannabis hospitality look like?
A: We’re Latino, Dominican and from the culture. We have been able to include every walk of life while not losing our morals, principles and values — while not losing our culture and our base.
Q: What do you think has been the key to your financial success?
A: The key has been we never started this because of strictly financial reasons. I was in the legacy market for 20 years. We did that for financial reasons.
We did this to really bring the community together.
The finances followed because it was something that we were passionate about.
Q: What is it going to take to support legacy to legal?
A: Right now we’ve hit a fork in the road. I always tell all of my comrades, my brothers and sisters that are out there in the legacy market, we have two choices to be different people in history.
You can either be Al Capone or Kennedy. They both did the same thing. One did not transition and when prohibition ended his notoriety ended. The other was legal and put his son in the White House.
I think that’s where we are now. The opportunity now is you can create wealth for generations to come. You’re still doing what you’re doing in the legacy market, you might have a short run, but you might not be able to create generational wealth.
Q: What are the resources you think legacy people need to get in?
A: Mentorship, examples like us and finance.
Q: How was that transition for you?
A: It’s been a journey. Our journey started five years ago after being in the legacy market and the culture of the streets. Now, I’m taking a masterclass in corporate cannabis and financial literacy in investment. I’m a double threat because I know both.
They’re two different worlds. What people from legacy markets understand, you can learn what corporate cannabis knows, they can’t learn what we know.
— Jelani Gibson
Digging up the facts on magic mushrooms
By Rob Mejia, a regular contributor to NJ Cannabis Insider, is an adjunct professor at Stockton University where he teaches the cannabis courses. He is also the author of “The Essential Cannabis Book” and “The Essential Cannabis Journal.” His cannabis education company is called Our Community Harvest.
Week after week, NJ Cannabis Insider brings you exclusive coverage of the happenings in the New Jersey cannabis market and beyond. But today we thought it would be useful to offer a primer on psilocybin (aka magic mushrooms), which are the subject of a recent bill championed by state Senate President Nick Scutari. The bill is called the Psilocybin Behavioral Health Access and Services Act. In simplest terms, it proposes that adults 21 and over can use, possess, and even grow up to four grams of psilocybin without penalty.
Grow? Yes, even though Scutari has not budged on homegrown cannabis — making New Jersey the only state with a medical cannabis program that does not allow homegrow — his bill would allow homegrown magic mushrooms.
To the subject at hand, what are magic mushrooms?
To begin with, if you follow cannabis news, you are seeing related articles about magic mushrooms/psilocybin (pronounced psy-lə-SY-bin) because mushrooms and cannabis share some common attributes and may be attracting a similar consumer base. The largest commonality is that they are both natural health products and psilocybin has special promise in treating depression and helping patients accept death. Here are a few basic facts about mushrooms:
• Mushrooms are fungi, but not all fungi are mushrooms
• Mushrooms are 90% water
• Over 10,000 types of mushrooms have been identified, but many remain undiscovered
• Mushrooms have been used for centuries for medicinal and spiritual reasons
• Researchers think that mushrooms containing psilocybin (over 200 species) cause a “hyperconnected brain” where parts of the brain that don’t usually communicate begin to make connections
• Cities such as Denver, Oakland, Santa Cruz, Washington, D.C., Cambridge, Seattle and even the state of Oregon recently decriminalized the possession and use of psilocybin mushrooms
But we still have a long way to go towards national decriminalization or legalization of so-called magic mushrooms. Psilocybin mushrooms remain illegal in most of the U.S. and, like cannabis, are considered a Schedule 1 drug – a substance that has a high risk of addiction and no recognized medical use.
But advocates tout mushrooms as a safe drug with health, psychological, spiritual, and emotional benefits. And those benefits are being taking seriously. Johns Hopkins, Yale, Stanford, UCLA, and other universities are conducting psilocybin research to see if they can help with conditions such as depression, nicotine dependence, Alzheimer’s, anxiety, opioid addiction, and PTSD.
Mushrooms parallel cannabis in many ways. Just like cannabis, the method of consumption makes a difference as to time of onset and how long the experience lasts. As with cannabis, factors such as size of dose, setting, product taken, individual health factors, and expectations may also influence the experience.
Mushrooms are often eaten dry or fresh (dry mushrooms are more potent than fresh mushrooms), sometimes mixed with food or consumed in tea. Effects start in 5 to 10 minutes if taken in tea, and in about 30 minutes when ingested. The mushroom high lasts 4 to 6 hours, but some users report a longer duration, and you won’t feel any lasting effects after 24 hours.
One increasingly popular service in the mushroom space is the use of “mushroom guides” who are experts in dosing, safety, species types and the ability to explain what will happen. As with each person, an experience can differ widely. But generally, with a modest dose defined as .5 to 1.5 grams, the user may feel the following effects which occur in phases:
• Sounds, colors, and objects may begin to look and sound different
• Some people may experience “visuals,” or mild hallucinations
On the positive side, psilocybin mushrooms can make you feel giggly, euphoric, bring on feelings of awe and connection, and provide energy.
On the negative side, consumers may feel nauseous, anxious, paranoid, and overwhelmed. But the negative experiences and feelings are usually traced back to the user’s state of mind when the journey began. To promote a positive outcome, find a safe and inviting environment, and have a willing mindset.
Another reason to work with an experienced mushroom guide is to avert the ingestion of poisonous mushrooms that can look remarkably similar to a magic mushroom. Every guide will tell you to avoid using substances such as alcohol, cannabis, and other mind-altering drugs at the same time to focus solely on your psilocybin adventure.
Overall, the experience of using mushrooms can best be described as a focused, connected way to interact with and examine your inner life. You will make connections that have never occurred to you. You are likely to appreciate those around you and nature in a more profound way. You will feel grounded and part of the earth. You may laugh, you may sing but you will emerge as a different person. May you travel safely and peacefully if you decide to take the journey.
Prof. Mejia’s Weed Corner is a regular column for NJ Cannabis Insider, focusing on news, trends and innovation in the local cannabis market. Reach out to him at [email protected]
(Photo by Hans Veth via Unsplash)
What mushrooms can do for N.J.
New Jersey just launched its recreational marijuana industry three months ago, and now its architect is proposing that the state legalize psilocybin, the hallucinogenic compound found in magic mushrooms.
The bill drafted by state Senate President Nick Scutari allows anyone over 21 to use the psychedelic drug and to grow it at home – no prescription necessary — on the premise that it carries therapeutic benefits for a broad list of maladies, including chronic depression, PTSD, substance abuse, and end-of-life stress.
The FDA concurs: It granted psilocybin “breakthrough therapy” status for treating depression in 2018, supporting dozens of research institutions across the globe – from UCLA to Imperial College in London – who are captivated by its potential as a miracle from nature.
To better understand these potential benefits, we spoke with Dr. Sunil Aggarwal, who co-founded the Advanced Integrative Medical Science (AIMS) Institute in Seattle and teaches at the University of Washington School of Medicine. This conversation with Dave D’Alessandro, NJ.com’s deputy editorial page editor, was edited for content.
Q. How long have you studied psilocybin in clinical settings?
A: My first exposure was when I participated in a research group at NYU in 2012, during my residency. I helped recruit cancer patients for that study, and I’ve taken coursework with the study leads. But I’m not permitted to prescribe psilocybin – it’s been a Schedule 1 drug since 1971 – so I can only counsel patients about their own self-directed use of psilocybin. I have asked the DEA for permission to use it as a therapeutic under something called the Right to Try Law, which permits experimental treatments for terminally ill patients. They have so far denied it, so I brought a suit against the DEA with support from the ACLU, the CATO Institute, nearly a dozen state attorneys general, and others.
Q. Who would you prescribe it to?
A: It’s a pretty wide range. It’s been given to patients with trauma, addiction, depression, life-threatening illnesses, PTSD. But I’ve also seen it used for spiritual growth; I’ve had patients who are aging, with medical issues, who want to recalibrate their purposes in life. That comes up fairly regularly.
Q. So how does psilocybin work?
A: Essentially, it enters your brain through the bloodstream and acts on a number of areas – notably the neurons, the cells responsible for sensory input – and disrupts what is known as the default mode network. Basically, it interrupts the way neurons are talking to each other. (Science author) Michael Pollan describes it as “shaking a snow globe.” The pieces don’t settle the same way as before: If those connections were reduced by stress or depression, this disruption creates new pathways for neurons to connect. The result is often described as a mystical state, with extreme feelings of bliss or euphoria, and those things actually have the therapeutic value.
Sometimes there is also fear and sadness, but more often it makes people feel more connected and alive. That is a profound experience for a Stage 4 cancer patient with a few months to live – a sense that there’s something more to the world other than this physical existence, perhaps a connection to something bigger than themselves, even a spiritual insight. And it often relieves the anxiety and depression that comes with the illness.
Q. With your background in hospice and palliative care, you must find it especially beneficial in terminal cases.
A: Yes. The thing is, there are no treatments in palliative care and hospice for the emotional and spiritual distress associated with terminal illness. There are some people with a terminal illness who are at peace, without worries or distress, but those cases are rare. So, psilocybin could potentially alleviate a lot of the difficulties most patients experience, namely the secondary symptoms associated with anxiety or dread – a depressed mood, isolation, a limitation of ability to connect with loved ones. For those things, it would be a game-changer.
There are volumes of research that supports that, but just as a clinician, I can tell you that we don’t do a good job in that area. We do the best we can with chaplains and nurses and social workers – who are great, don’t get me wrong – but sometimes that’s just not enough. You need something stronger.
Q. Is relief from physical pain a part of the therapeutic benefits?
A: Yes. Sometimes it’s described as being ‘a little less in your body,’ an ability to distance yourself from the pain. The earliest studies from the 60s established that. But that’s not really the main mechanism here, it is only a part of it. There is a detachment: Pain is less prominent because you don’t feed it with anxiety. Pain and anxiety usually feed each other.
Q. Public acceptance of new drugs is always slow, and “magic mushrooms” seem especially stigmatized. But what is the general attitude from the medical community?
A: Well, there are dozens of major academic medical centers in the United States – and more around the world – who have invested many millions in research. Basically, if you’re going to put up a shingle on this, you want to be public about it. That’s not stigma, that’s a serious curiosity and focused study. In a different area of medicine – say, pediatric addiction medicine, or pediatric psychiatry — there might be a skepticism and concern.
Drugs must go through the clinical trial process, which has three phases. Psilocybin has already passed Phase 1, which means you have demonstrated that they are safe. We have a federal law that says that those substances are legal to be used in patients with life-threatening illness if their doctors feel it would be beneficial. That’s the Right to Try law I mentioned earlier.
Q. Every synopsis I’ve seen emphasizes that mushrooms are not addictive, but it’s generally agreed that doing them without supervision is reckless, and that people with serious illnesses such as schizophrenia are never used in studies. What else do we need to know about precautions?
A: A controlled, supportive environment is critical – a good therapeutic “container,” we call it, where the patient is well-prepared, well-screened, and well supported in the aftermath. Human beings have been using these substances since before recorded history, and they’re still using them, but if we had some policy initiatives, we would be able to help more people and create a safe container for all.
Q. If New Jersey passes a legalization law, what would it look like? Would we need an infrastructure, such as a network of clinics?
A: I currently sit on our state’s Psilocybin Work Group with public health experts and government officials from around Washington State, and we’re charged with studying Oregon’s rollout and making recommendations for when our law is ready to go. And I think most of us really don’t want to just have service centers for psilocybin. We want to think about home use, about micro-dosing if we can, and other access options.
Because clinical-only is expensive. There are times where you’d want medical or mental-health professionals in the room, but I don’t think that’s necessarily true for all. If you have a psychiatric issue, you need specialists. But if (supervision) is restricted to people with licenses — doctors and psychotherapists – it becomes very expensive. Generally, none of their fees would be covered by your insurance company, and it would be cost-prohibitive: You’re not just sitting with them for 30 minutes, you’re sitting with them for 5-6 hours. That’s one of the concerns that they’re seeing Oregon now.
This story first appeared on NJ.com as a subscriber exclusive. NJCI members get it for free
(Photo by J. Scott Applewhite | Associated Press)
Bill to end prohibition, boost research, social equity introduced to U.S. Senate
Long-awaited U.S. Senate cannabis legislation that would end the federal ban on marijuana while encouraging research and taking steps to help minority communities hardest hit by the war on drugs was introduced Thursday.
The Cannabis Administration and Opportunity Act would leave it to the states to decide whether to legalize the drug. Many, including New Jersey, already have, putting them in conflict with federal law. Those state-legal businesses would be able to obtain checking accounts, credit cards and other financial services now denied to them.
The bill would expunge federal cannabis convictions and encourage states to follow suit; require the Food and Drug Administration to set strong cannabis health, safety and labeling standards; encourage research into the drug; impose a federal excise tax of 5% to 12.5% for smaller businesses and 10% to 25% for larger concerns; and direct the National Highway Traffic Safety Administration to address drugged driving, requiring a standard for cannabis-impaired driving within three years.
“As more states legalize cannabis and work towards reversing the many injustices the failed war on drugs levied against Black, brown, and low-income people, the federal government continues to lag woefully behind,” said U.S. Sen. Cory Booker, one of the bill’s chief sponsors along with Senate Majority Leader Chuck Schumer, D-N.Y., and Finance Chair Ron Wyden, D-Ore.
RELATED: Booker plans Senate hearing to address marijuana laws’ harm to Black residents
“With strong restorative justice provisions for communities impacted by the drug war, support for small cannabis businesses, and expungement of federal cannabis offenses, this bill reflects long overdue, common sense drug policy,” Booker said.
Federal law would still prevent using or selling cannabis in states that have not legalized the drug. The Department of Justice would provide grants to help small law enforcement departments hire officers, investigators and community outreach specialists to combat black market sales.
The bill would limit the sale of cannabis to those 21 and older, and fund programs to prevent youth marijuana use. The FDA’s new Center for Cannabis Products would set labeling standards, including potency and servings.
The Department of Veterans Affairs and Indian Health Service would offer recommendations about the use of medical marijuana by patients, and work to prevent people from buying large quantities of the drug in states where it is legal in order to sell it elsewhere.
Those harmed by the War on Drugs would get access to financing to enter the cannabis business and those who use marijuana wouldn’t face the loss of federal benefits such as housing or student loans. Marijuana testing for federal workers would be limited to those employees in areas such as national security, law enforcement, and commercial transportation.
The FDA and the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau would take over jurisdiction over marijuana from the Drug Enforcement Agency and would regulate it like alcohol and tobacco. Legal marijuana businesses would be able to deduct their expenses like other enterprises.
Federal taxes would be used to help communities and individuals hardest hit by the war on drugs, including grants to community-based organizations to offer job training, legal aid, mentoring and literacy programs. Loans would be made directly to small businesses owned by socially and economically disadvantaged individuals, and to lenders who would make those loans.
And federal research into the medical properties would be increased, including offering grants to develop research facilities and universities, especially minority-serving institutions and Historically Black Colleges and Universities.
“Senators Schumer, Booker, and Wyden listened to our concerns as regulators,” said the Cannabis Regulators of Color Coalition in a statement. The CRCC said the bill incorporates “much-needed revisions to the draft, such as prioritizing Minority Serving Institutions (MSI), including HBCUs, in the bill’s education infrastructure and adding several of CRCC’s proposed banking amendments, which will help close the gap on inequitable access to capital and other critical resources within the cannabis industry, particularly for historically-excluded and minority entrepreneurs.”
The bill was more than year in the making as Democrats took control of the Senate and Schumer vowed to introduce legislation with the hope it would attract the 60 votes needed for passage in their chamber.
That would require at least 10 Republicans to vote with every Democrat, but many GOP senators now hail from states that have legalized cannabis for medical or personal use.
“The introduction of comprehensive cannabis reform legislation in the Senate, by none less than the majority leader himself, is the strongest sign yet that cannabis prohibition in America is nearing its end,” said Steve Hawkins, chief executive of the U.S. Cannabis Council.
There were some dissenting voices, however.
“Under the guise of social justice, increased entrepreneurship, and other false narratives, this bill will guarantee our next slow motion public health crisis — all while bypassing stringent review/approval processes other psychoactive drugs had to clear,” said former Rep. Patrick Kennedy, D-R.I., a co-founder of Smart Approaches to Marijuana.
“By commercializing legal marijuana, tobacco companies, liquor companies, financial institutions, and the pharmaceutical industry stand to make billions. Let’s not lose sight of who the real ‘winners’ are here.”
The House twice has passed legislation to end the federal ban on cannabis and help communities and individuals hardest hit by the war on drugs. But until now, the Senate has refused to go along.
“A majority of Americans now support legalizing cannabis, and Congress must act by working to end decades of over-criminalization,” Schumer said. “It is time to end the federal prohibition on cannabis.”
In addition, the Senate never has taken up incremental steps such as the Secure and Fair Enforcement, or SAFE Banking Act, even forcing it out of unrelated legislation that Democrats have succeeded in adding it to in the House.
Booker has objected to passing SAFE Banking on its own, saying that the monied interests pushing for that bill would lose their interest in also championing restorative justice issues if their priority is enacted.
But Hawkins said that Congress should move now on more incremental cannabis legislation.
“The ambitious and sweeping nature of the bill should not distract Congress from advancing limited yet critical reforms, such as expungement and the SAFE Banking Act, that are immediately within reach,” he said.
— Jonathan D. Salant | NJ.com
Bootcamp time! Sept. 15 event aimed to boost small businesses.
NJ Cannabis Insider Live has designed a new learning experience set for Sept. 15.
Presented by Weedmaps, the all-day, multi-track conference will put an emphasis on serving New Jersey’s small-businesses, temporary permit-holders and future operators.
“We’re billing our fall conference as a bootcamp for new businesses and an accelerator for cannabis companies that are already off the ground,” said Enrique Lavin, NJ Cannabis Insider’s publisher and editor. “Instead of hosting panels with multiple speakers, we want to create more of a focused classroom setting with industry leaders as the educators. We want attendees to walk away with the tools, information and partners they need to succeed.”
The bootcamp, which will run from 8 a.m.-5 p.m. at the Crown Plaza Princeton, will help small businesses working toward getting full approval by the state to open, as well as future applicants who are serious about getting into the cannabis space.
Programming will be complete with immersive workshops, interactive panels and niche discussions geared toward both the budding business owner and seasoned cannabis professional.
With two carefully curated program tracks, ample networking sessions and a vendor showcase, attendees will walk away with the viable tools, information and resources needed to establish and expand. Several of the educational programs expand on NJ Cannabis Insider’s popular CannaTalk sessions.
For start-up businesses and newcomers, expect informative and hands-on sessions with actionable takeaways, including:
- How to write a business plan
- Steps to submitting a permit application to the state
- Financing your business
- Everything you need to know about real estate and building
For more established cannabis businesses, expect to learn about emerging trends, advancements in cannabis technology and best practices to help your cannabis business continue to thrive.
In addition to Weedmaps, sponsors and vendors so far include:
Choose from full-day or half-day admission to further customize your experience. Subscribers discount code is: NJCISUB. Register here.
We are working on the final programming, speakers and exhibitors. To find out how to get involved with ads or sponsorships, contact Heather Long or Kristen Ligas. Contact Enrique Lavin about speakerships.
Live virtual job fair July 26-27
NJ.com, in collaboration with NJ Cannabis Insider, will host Cannabis Insider Live Virtual Job Fair July 26-27. Job seekers should register here.
Applicants will be able to upload their resume, browse exhibitor booths for new opportunities, and live chat with recruiters.
During this two-day virtual event, recruiters can chat with prospects who are applying to open positions. Hundreds of job seekers are expected to join the fair.
Live chat sessions are:
- July 26 9 a.m.-noon
- July 27 1-4 p.m.
The virtual booths will remain live through Aug. 23, allowing visitors to explore and apply to jobs at their convenience. More than 4,000 job-seekers attended our May hiring event. Register here.
In addition, CannabisInsiderJobs.com, a website dedicated to finding a career in the cannabis industry, recently partnered with a company aligned in this mission.
CareersinCannabis.com, powered by engin, provides the canna-curious an industry standardized way to build a profile that matches candidates to cannabis job opportunities in their local community or nationally.
“CareersinCannabis.com matches job seekers with relevant jobs in the candidate’s local area, and right now several of our clients are actively seeking talent in the emerging New Jersey market,” said Ben Kogelman, head of Customer Success at engin.
“We developed a streamlined way for candidates to represent their transferable skills and experience through an easy resume-builder process,” Kogelman said. “By creating a profile on CareersinCannabis.com, candidates increase their visibility to companies seeking to hire qualified talent quickly, leading to a much better fit for both candidate and company alike.”
— Gabby Warren
Jelani Gibson is the lead reporter for Cannabis Insider. He previously covered gun violence for the Kansas City Star.
Suzette Parmley is the cannabis reporter for The Star-Ledger and NJ.com. She previously worked at the New Jersey Law Journal and The Philadelphia Inquirer covering law, business and politics.
Susan K. Livio is a Statehouse reporter for The Star-Ledger and NJ.com who covers health, social policy and politics
Jonathan D. Salant is Washington correspondent for The Star-Ledger and NJ.com.